ArticleAllergy, asthma & immunology research2018
Decreased CRTH2 Expression and Response to Allergen Re-stimulation on Innate Lymphoid Cells in Patients With Allergen-Specific Immunotherapy.
Article in Allergy, asthma & immunology research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 40 citations in OpenAlex.
- Updates on Immunologic Responses to Aeroallergen Immunotherapy Since the 2011 US Practice Parameters on Allergen Immunotherapy.Current allergy and asthma reports · 2026Review
- Article
- Sublingual Immunotherapy Decreased the Serum Levels of Interleukin-36Mediators of inflammation · 2024Article
- KAAACI Guidelines for Allergen Immunotherapy.Allergy, asthma & immunology research · 2023Review
- Deciphering Differential Behavior of Immune Responses as the Foundation for Precision Dosing in Allergen Immunotherapy.Journal of personalized medicine · 2023Review
- Allergen immunotherapy combined with Notch pathway inhibitors improves HDM-induced allergic airway inflammation and inhibits ILC2 activation.Frontiers in immunology · 2023Article
- Sublingual Immunotherapy for Japanese Cedar Pollinosis: Current Clinical and Research Status.Pathogens (Basel, Switzerland) · 2022Review
- How the Immune System Responds to Allergy Immunotherapy.Biomedicines · 2022Review
- ILCs and Allergy.Advances in experimental medicine and biology · 2022Article
- [The research progress of mechanism of allergen immunotherapy in allergic rhinitis].Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology head and neck surgery · 2021Review
- Sublingual Immunotherapy: How Sublingual Allergen Administration Heals Allergic Diseases; Current Perspective about the Mode of Action.Pathogens (Basel, Switzerland) · 2021Review
- Allergic Rhinitis: What Do We Know About Allergen-Specific Immunotherapy?Frontiers in allergy · 2021Review
- Mechanisms of Allergen Immunotherapy in Allergic Rhinitis.Current allergy and asthma reports · 2020Review
- Mechanisms of allergen-specific immunotherapy for allergic rhinitis and food allergies.Bioscience reports · 2020Review
- Role of innate lymphoid cells in allergic diseases.Allergy and asthma proceedings · 2019Review
- Innate Lymphoid Cells in Mucosal Immunity.Frontiers in immunology · 2019Review
- Biomarkers in oral immunotherapy.Journal of Zhejiang University. Science. BReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
purposeGroup 2 innate lymphoid cells (ILC2s) have been implicated in the pathogenesis of allergic disease. However, the effect of allergen-specific immunotherapy (AIT) on ILCs remains to be clarified. The aim of this study was to evaluate the levels of ILC subsets in allergic rhinitis (AR) patients in response to house dust mite (HDM)-specific immunotherapy.
methodsWe enrolled 37 AR patients undergoing AIT (16 responders and 11 non-responders) for 2 years, 35 HDM AR patients and 28 healthy subjects. Peripheral blood mononuclear cells (PBMCs) were analyzed by flow cytometry to identify ILC subsets. Stimulation of ILC2s with recombinant allergen-specific protein was used to determine ILC2's activation (CD69 expression).
resultsResponder AIT patients and healthy subjects had a decreased frequency of circulating ILC2s compared to non-responder AIT and AR patients. Conversely, ILC1s from responder AIT patients and healthy subjects showed increased frequency compared to non-responder AIT and AR patients. The frequency of ILC3s natural cytotoxicity receptor (NCR)⁺ and NCR⁻ in responder AIT patients was significantly lower compared to AR patients and healthy subjects. The ILC1: ILC2 proportion in responder AIT patients was similar to that of healthy subjects. PBMCs from patients who were responders to AIT had a significantly lower expression of the activation marker CD69 on ILC2s in response to allergen re-stimulation compared to AR patients, but no difference compared to non-responder AIT patients and healthy subjects.
conclusionsWe propose that AIT might affect ILC responses. The activation of ILC2s was reduced in AR patients treated with AIT. Our results indicate that a relative ILC1/ILC2 skewed response is a possible key to successful AIT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.